French medtech firm Gleamer has developed AI-powered medical imaging solutions for radiography - its extending its portfolio of solutions to CT scans and mammography.
Founded in 2017, by Christian Allouche, Alexis Ducarouge, and Dr. Nor-eddine Regnar, by now it has quite the reach with its clinical diagnostic solutions used worldwide, 'serving over 6,500 users in 650 institutions, spanning 24 countries, its solutions process more than a million medical examinations each month'.
Gleamer has raised a Series B funding round of €27 million, bringing its total funding amount date amount to €35.5 million. The fresh funding will fuel the hiring of talent in the European and US teams as the firm bids to capture more footing in those markets.
The round is led by Supernova Invest and Heal Capial and includes Gleamer’s long-term backers XAnge, Elaia, Bpifrance, MACSF, Crista Galli Ventures, and UI Investissement, as well as several European radiologists.
“This new round of funding will allow us to deepen Gleamer's mission of making AI the new standard of care in radiology. Our aim is to increase diagnostic accuracy and improve patient care and the efficiency of clinical practices for health professionals. We are delighted to have the support of Supernova Invest and Heal Capital, who not only have recognised deep expertise in this field, but also know how to support the commercial and technological development of growing companies positioned on global markets, such as Gleamer,” says Christian Allouche, CEO and co-founder of Gleamer.
"Gleamer is positioned as a leader in the use of AI in radiology, with a catalog of solutions to improve the diagnosis of numerous pathologies and the effectiveness of care, for the benefit of patients. Supernova Invest is delighted to support a visionary team with unique growth potential, redefining the contours of radiology and medical imaging through disruptive technological solutions that can be deployed on a large scale. This is a company whose business and societal models, and technological challenges are in line with Supernova Invest's DNA,” says Rémi Spagnol, Investment Director at Supernova Invest.